

**REMARKS**

A copy of the Notice of Incomplete Reply, a paper-copy of the Sequence Listing, and a computer readable form (floppy disk) of the Sequence Listing are enclosed. It is respectfully submitted that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned attorney hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.


In view of the amendments, remarks and enclosures, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825. Reconsideration and withdrawal of the Notice of Incomplete Reply is earnestly solicited.

If any additional fees are incurred for entry and consideration of this Amendment, the Examiner is authorized to charge any fees or credit any overpayment to Deposit Account No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for the Applicant

By:



Thomas J. Kowalski  
Reg. No. 32,147  
Samuel H. Megerditchian  
Reg. No. 45,678  
(212) 588-0800

Enclosures: Sequence Listing (diskette and paper);  
Copy of Notice of Incomplete Reply; and  
Return receipt postcard.

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Page 6, under the heading --Detailed Disclosure--:

Hence, one embodiment of the invention pertains to a fusion polypeptide which comprises a first amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from the *M. tuberculosis* protein ESAT-6 (SEQ ID NO: 1), and a second amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from the *M. tuberculosis* protein Ag85B and/or a stretch of amino acids which protects the first amino acid sequence from *in vivo* degradation or post-translational processing (SEQ ID NO: 2). The first amino acid sequence may be situated N- or C-terminally to the second amino acid sequence, but in line with the above considerations regarding protection of the ESAT-6 N-terminus, it is preferred that the first amino acid sequence is C-terminal to the second.